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Abstract The sequence of EspB, a secreted protein required for
virulence of enteropathogenic Escherichia coli (EPEC), reveals a
motif common to enzymes that bind pyridoxal phosphate.
Pyridoxal phosphate was not found by fluorometry in concen-
trated supernatants of EPEC cultures that contain EspB.
Plasmids containing cloned espB, in which the lysine residue
conserved in the motif was substituted with either an arginine or
methionine residue, remained capable of complementing an espB
deletion mutant to restore EspB function. The results of these
studies do not support a role for pyridoxal phosphate in EspB
function. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Enteropathogenic Escherichia coli (EPEC), a leading cause
of infantile diarrhea in the developing world, disrupts host cell
microvilli, induces rearrangements of actin, and initiates the
formation of a cup-like pedestal to which the bacteria inti-
mately adhere in a process known as the attaching and e¡ac-
ing e¡ect [1]. A chromosomal pathogenicity island encoding a
type III secretion pathway is necessary and su⁄cient for this
attaching and e¡acing e¡ect [2,3] and is used by EPEC to
secrete several proteins [4] including the translocated intimin
receptor (Tir). Tir is inserted into the host cell membrane,
where it serves as the receptor for the bacterial outer mem-
brane protein intimin [5], which is required for intimate at-
tachment. EspB, another protein secreted via the type III
system, is required for EPEC virulence in an adult volunteer
model [6] and for numerous in vitro phenotypes attributed to
EPEC including attaching and e¡acing activity [7], activation
of NF-UB [8], and in polarized monolayers changes in short-
circuit current [9], transepithelial electrical resistance [10], and
transmigration of leukocytes [11]. The precise function of
EspB is not known, but since it is required for translocation
of Tir into the host cell membrane [5], it may be considered
part of the EPEC translocation apparatus. On the other hand,
EspB itself is inserted via the type III system into the host cell
[12,13] and expression of EspB within host cells leads to dra-
matic changes in the cytoskeleton [14], suggesting that EspB
may itself be a bacterial e¡ector protein. Analysis of the pre-
dicted amino acid sequence of EspB from EPEC strain E2348/
69 revealed the presence at residues 136^145 (TSAKSIGTVS)
of a near perfect consensus sequence common to the pyridoxal
5P-phosphate-binding motif of several type II aminotransfer-
ase enzymes [7]. The consensus pattern for this type of enzyme
is T-[LIVMFYW]-[STAG]-K-[SAG]-[LIVMFYWR]-[SAG]-
X(2)-[SAG], where X is any amino acid and the indicated
alternative amino acids are allowed at bracketed positions.
Of particular note is the presence, at position four, of a crit-
ical lysine residue, which forms a covalent bond with pyridox-
al 5P-phosphate [15]. In the EspB protein from EPEC strain
E2348/69, there is a single amino acid di¡erence at position
two, placing a serine at this position rather than one of the
seven amino acids previously recognized in the consensus pat-
tern. Since substitution of a single amino acid, other than at
the site of the critical lysine residue, does not necessarily pre-
clude interaction of pyridoxal phosphate with binding do-
mains in other transaminases [16], we sought to determine
whether EspB incorporates pyridoxal phosphate at this site.
To test the hypothesis that EspB uses pyridoxal phosphate as
a cofactor for its function, we sought £uorometric evidence of
pyridoxal phosphate in EPEC supernatants containing EspB
and performed site-directed mutagenesis of the putative pyr-
idoxal phosphate-binding motif.
2. Materials and methods
2.1. Bacterial strains and plasmids
The prototypic EPEC serotype O127:H6 strain E2348/69 and iso-
genic strain UMD864 containing an in-frame deletion of the espB
gene have been described [7]. Plasmids and oligonucleotides used
are indicated in Table 1.
2.2. Preparation of culture supernatants
Protein samples were prepared from supernatants concentrated us-
ing a stirred-cell ¢ltration device as previously described [17]. The
protein concentration for each sample was determined using the bi-
cinchoninic acid assay (Pierce, Rockford, IL, USA). The percent of
EspB present in each supernatant preparation was estimated by Coo-
massie blue staining and the concentration of EspB was calculated on
this basis.
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2.3. Fluorometric detection of pyridoxal phosphate
Samples of concentrated secreted proteins were assayed for pyridox-
al phosphate in two independent experiments using the method of
Adams [18], which takes advantage of the high £uorescence yield of
pyridoxal phosphate after reaction with cyanide. Brie£y, each protein
sample was suspended in potassium phosphate bu¡er, acidi¢ed by the
addition of an equal volume of 11% TCA, incubated with KCN and
adjusted to a ¢nal pH of 3.8. Samples were excited at 325 nm in a
Shimadzu RF 5301 PC £uorometer and the emission spectra from 370
to 520 nm were recorded.
2.4. Site-directed mutagenesis
A two-step overlap PCR technique was used to engineer mutations
of the pyridoxal phosphate-binding domain. The plasmid pMSD3 was
used as the template for each PCR reaction. Oligonucleotides Donne-
3 and Donne-4 bracket the 2.3 kb region of DNA in which the espB
gene lies and incorporate a SalI and SphI site, respectively. Two addi-
tional oligonucleotides, Donne-132 (or Donne-201) and Donne-133
(or Donne-202), are complementary and correspond to the sequence
of the pyridoxal phosphate-binding site with a single nucleotide
change at position 526 or 527 of the espB gene which, when trans-
lated, changes the amino acid 139 from a lysine to arginine or me-
thionine, respectively. Donne-3 and Donne-133 (or Donne-202) and
Donne-4 and Donne-132 (or Donne-201) were used in separate reac-
tions to amplify the 2.3 kb template containing the espB gene. The
result is two half products with a complementary 18 bp overhang
corresponding to the pyridoxal phosphate-binding sequence with the
introduced mutation. These products were then combined and sub-
jected to ampli¢cation using Donne-3 and Donne-4 to regenerate the
recombinant espB gene, containing the desired point mutation. The
second ampli¢cation products were then cloned into the pACYC184
vector via the SalI and SphI sites. The resulting plasmids containing
the K139R and the K139M mutations were con¢rmed by sequence
analysis and designated pKT.K139R and pCO.K139M, respectively.
In each case, PCR reactions were carried out for 30 cycles of dena-
turation at 94‡C for 1 min, annealing at 55‡C for 1 min and extension
at 72‡C for 2 min. DNA sequencing of plasmid templates was per-
formed at the University of Maryland Biopolymer Laboratory using a
model 373A sequencer (Applied Biosystems, Foster City, CA, USA).
2.5. Fluorescence actin staining test
The £uorescence actin staining test, which measures the accumula-
tion of ¢lamentous actin beneath areas of attaching and e¡acing bac-
teria [19], was performed in chamber slides as previously described
[20].
3. Results and discussion
We used a £uorometric method to determine whether
EPEC culture supernatants containing EspB also contain pyr-
idoxal phosphate. Fig. 1 shows the absorption spectra, after
excitation at 325 nm, for the supernatant proteins containing
1 WM of secreted EspB from the wild type strain, E2348/69,
and an equal concentration of protein from the espB deletion
mutant, UMD864, respectively. By comparison to the spectra
for the puri¢ed pyridoxal 5P-phosphate samples, and phos-
phorylase A, a pyridoxal phosphate containing enzyme, it is
apparent that there is little, if any, pyridoxal phosphate
present in the supernatant samples assayed. To insure that
pyridoxal phosphate, if present, could be detected in EPEC
supernatants using this assay, we also analyzed supernatant
proteins from the espB deletion mutant UMD864 after the
addition of 1 WM pyridoxal phosphate. If EspB binds pyri-
doxal phosphate on an equimolar basis as predicted, then the
addition of 1 WM of pyridoxal phosphate to the deletion mu-
tant sample should have the e¡ect of bringing the intensity of
the emission spectra for UMD864 up to the level of the wild
type strain. As seen in Fig. 1, the absorption spectrum for this
sample was intermediate between the 0.2 and 2.0 WM pyridox-
al phosphate controls, with a much greater peak at 420 nm
than that of the wild type sample. These results demonstrate
that pyridoxal phosphate is not present as cofactor for EspB
upon secretion of the protein from EPEC.
To address the possibility that the pyridoxal phosphate
motif is important to the function of EspB during infection,
we generated two espB constructs with de¢ned mutations in
the pyridoxal phosphate-binding site (Table 1). Plasmids con-
taining these mutant espB alleles were then introduced into
the espB deletion strain, UMD864. The espB mutant con-
structs were tested for their ability to complement UMD864
to restore the attaching and e¡acing phenotype. This process
may be monitored by £uorescence microscopy using £uores-
cein isothiocyanate-conjugated phalloidin, which binds to ac-
Table 1
Plasmids and oligonucleotides used in this study
Designation Sequence or source Description or purposea
pMSD3 [7] Plasmid carrying a 2.3 kb BglII fragment of EPEC DNA that
includes the espB gene
pACYC184 [22] Cloning vector containing chloramphenicol and tetracycline resistance
pKT.K139R This study Plasmid carrying the espB gene with the K to R mutation in the PLP
motif
pCO.K139M This study Plasmid carrying the espB gene with the K to M mutation in the
PLP motif
Donne-3 5P-GGG TCG ACG ATC TAC GCG GAT GGA CA-3P Upstream end of the 2.3 kb BglII fragment of pMSD3, containing
espB, with the SalI site incorporated
Donne-4 5P-GGG CAT GCG ATC TTT TAT CGT TTT CA-3P Downstream end of the 2.3 kb BglII fragment with the SphI site
incorporated
Donne-19 5P-GTT GAA CGC GAA ATC C-3P Nucleotides 698^683 of espB ; used to sequence the K to R mutation
Donne-132 5P-GCC GCT TCT ACT TCT GCG AGG TCT ACT GGT
ACA GTC-3P
Nucleotides 508^530 of espB ; with Donne-133 introduces a change at
nucleotide 417 to generate the K to R mutation
Donne-133 5P-CTC GCA GAA GTA GAA GCG GCT TGC-3P Nucleotides 527^503 of espB ; with Donne-132 introduces the K to R
mutation
Donne-201 5P-GCC GCT TCT ACT TCT GCC ATG TCT ATC GGT
ACA GTC-3P
Nucleotides 507^543 of espB ; with Donne-202 introduces a change at
nucleotide 416 to generate the K to M mutation
Donne-202 5P-ATG GCA GAA GTA GAA GCG GCT TGC-3P Nucleotides 550^526 of espB ; with Donne-201 introduces the K to M
mutation
aNucleotide positions according to GenBank^EMBL accession number Z21555.
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cumulated ¢lamentous actin underneath adherent bacteria
[19]. If EspB requires the pyridoxal phosphate motif to per-
form its function, then substitution of the critical lysine resi-
due in the pyridoxal phosphate-binding site with either argi-
nine or methionine would be expected to abolish the ability of
EspB to recruit ¢lamentous actin in host cells. We found that
recombinant strains containing either of the pyridoxal phos-
phate point mutation constructs were able to cause the con-
densation of actin under their sites of adherence, as was wild
type (data not shown). In contrast, the espB mutant lacking a
complementing plasmid was unable to recruit actin. Thus,
substitutions at lysine 139 in the putative EspB pyridoxal
phosphate-binding site had no e¡ect on the function of the
EspB protein.
The results of this study fail to support the earlier sugges-
tion that EspB is a pyridoxal phosphate-dependent, type II
transaminase. That we could not detect pyridoxal phosphate
in samples containing ample quantities of EspB, while we
were able to detect the cofactor when it was added exoge-
nously, clearly indicates that it is not associated with EspB
in signi¢cant quantities. To more de¢nitively exclude a role of
pyridoxal phosphate in EspB function, we replaced the critical
Fig. 1. Emission spectra of bacterial supernatants after excitation at 325 nm. Proteins secreted by either the wild type EPEC strain, E2348/69,
or the espB deletion strain, UMD864, were assayed for the presence of pyridoxal phosphate by £uorometry as described in Section 2. For wild
type supernatant samples 1 WM EspB was tested (a). For UMD864, an equivalent amount of protein was assayed (+). An equivalent amount
of secreted proteins from strain UMD864 to which 1 WM pyridoxal phosphate was added (R), 2 WM phosphorylase A (F), 0.2 WM pyridoxal
phosphate (U) and 2 WM pyridoxal phosphate (8) were also tested as controls.
Table 2
The pyridoxal phosphate motif of EspB from E. coli strain E2348/69, comparable regions of the EspB sequence from other attaching and e¡ac-
ing strains, and the consensus pyridoxal phosphate motif
Strain Accession number Sequence
E2348/69 Q05129 T S A K S I G T V S
C. rodentium AAD51754 A S A K S V N T A S
EDL933 AAC31499 A S S K A A G A A S
413.89-1 CAA67984 T S S K A I D A A S
E65/56 AAD34584 T S S K A I D A A S
4221 AAD12778 T S S K A I D A A S
RDEC-1 AAB69980 T S S K A I D A A S
B10 AAC82360 T S S K A I D A A S
Pyridoxal phosphate consensus T [LIVMFYW] [STAG] K [SAG] [LIVMFYWR] [SAG] X X [SAG]
Residues in bold di¡er from the consensus sequence.
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lysine residue that would represent the site of covalent binding
to pyridoxal phosphate with either arginine, a relatively con-
servative replacement, or methionine, which is similar in size,
but lacks the amine residue necessary for forming a Schi¡’s
base with the cofactor. Even though this lysine residue is
absolutely conserved in all EspB sequences reported to date
(Table 2), neither replacement had any detectable e¡ect on
function, clearly excluding an important role of pyridoxal
phosphate in EspB function. That pyridoxal phosphate is
not involved in EspB function is surprising, but not unprece-
dented. There are several proteins that have been reported to
possess the consensus pattern for pyridoxal phosphate-bind-
ing but do not bind or require this cofactor for their function
[21]. In addition, as more EspB sequences have accumulated,
it has become apparent that EspB proteins from other attach-
ing and e¡acing strains have even more variation from the
consensus pyridoxal phosphate-binding motif than does the
original sequence (Table 2). We therefore conclude that
EspB does not require the cofactor pyridoxal phosphate for
its essential function in EPEC infection.
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